Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Public ClinicalTrials.gov record NCT02178722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Study identification
- NCT ID
- NCT02178722
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 444 participants
Conditions and interventions
Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
- Endometrial Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Gastric Cancer
- Lung Cancer
- Lymphoma
- Renal Cell Carcinoma (RCC)
- Ovarian Cancer
- Solid Tumors
- UC (Urothelial Cancer)
- Melanoma
- Bladder Cancer
- Triple Negative Breast Cancer (TNBC)
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2014 (Actual)
- Primary completion
- Nov 26, 2018 (Actual)
- Completion
- Nov 6, 2020 (Actual)
- Last update posted
- Feb 14, 2022
2014 – 2020
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| US Davis Cancer Center | Sacramento | California | 95817 | — |
| University Of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center | Farmington | Connecticut | 06030-1601 | — |
| Miami Cancer Institute at Baptist Health, Inc | Miami | Florida | 33176 | — |
| Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute | Atlanta | Georgia | 30342 | — |
| The University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| St. Francis Cancer Center | Topeka | Kansas | 66618 | — |
| Greater Baltimore Cancer Center | Baltimore | Maryland | 21204 | — |
| St. Agnes Hospital Cancer Institute | Baltimore | Maryland | 21229 | — |
| The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division) | Bethesda | Maryland | 20817 | — |
| University of Michigan Hospital and Health Systems | Ann Arbor | Michigan | 48109 | — |
| Health Partners Institute | Saint Louis Park | Minnesota | 55426 | — |
| Hackensack University Medical Center - John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| The Christ Hospital Hematology Oncology, Lindner Research Center | Cincinnati | Ohio | 45219 | — |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| University of Pittsburgh Medical Center Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Greenville Health System Cancer Institute | Greenville | South Carolina | 29605 | — |
| West Cancer Center | Germantown | Tennessee | 38120 | — |
| Sarah Cannon Research Institute at Tennessee Oncology | Nashville | Tennessee | 37203-2173 | — |
| University Of Texas Southwestern Medical Center At Dallas | Dallas | Texas | 75390 | — |
| Virginia Cancer Specialists | Arlington | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02178722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 14, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02178722 live on ClinicalTrials.gov.